Cortisone: A Problem in Pharmaceutical Marketing
William McK. Jefferies, M.D. (Retired)
When cortisone was first reported to produce dramatic beneficial effects
in patients with rheumatoid arthritis in 1949(1), its use was welcomed
as a major advance in medical therapy. The fact that it was a normal hormone,
the only hormone that is absolutely essential for life, and that it also
produced similar dramatic beneficial effects in patients with other autoimmune
disorders, in those with chronic allergic disorders, and in those with
many other illnesses, resulted in its discoverers being awarded the Nobel
Prize. Yet within a few years patients receiving cortisone or its derivatives
had developed so many serious and sometimes fatal side effects that these
medications developed a reputation for being dangerous drugs whose use
should be limited to patients with serious illnesses that could not be
helped by any other treatment. Meanwhile it became evident that cortisone
must be converted to hydrocortisone before having its characteristic physiologic
effects and chemists pointed out that cortisol was a more proper term for
hydrocortisone, thus adding to the confusion of most physicians and patients.
When serious side effects developed in patients receiving the large dosages
of cortisone or hydrocortisone (cortisol) that were thought to be necessary
for therapeutic effects, derivatives such as prednisone or triamcinolone
were introduced, but except for less tendency to produce retention of salt
and water (edema), the derivatives often produced any or all of the undesirable
side effects of excessive amounts of the normal hormone. Hence cortisone
and cortisol developed a reputation for being dangerous drugs whose use
should be confined to patients with serious, life-threatening illnesses
that would not improve with any other treatment.
Having trained at the Massachusetts General Hospital under Dr. Fuller Albright,
a pioneer in the study of adrenocortical function, I was developing an
endocrine clinic and research laboratory at Western Reserve University
Hospitals in Cleveland, Ohio and I saw every patient admitted for treatment
with cortisone or its derivatives for the first two years that these medications
were available. In 1955 I wrote a review article summarizing the problems
that existed at that time that was published in the New England Journal
of Medicine entitled, "The Present Status of ACTH, Cortisone and Related
Steroids in Clinical Medicine" (2). During this time I determined
that the duration of effect of a single dose of cortisol was approximately
8 hours and that normal human adrenals produced the equivalent of 35 to
40 mg of cortisol daily when taken as tablets by mouth 4 times daily, before
meals and at bedtime in the absence of unusual stress.
Meanwhile I also began to work in an infertility clinic associated with
Western Reserve University and found that many of its women patients had
evidence of mild disorders of adrenal function that improved when they
were given small, subreplacement dosages of cortisone or cortisol (3).
During the next twenty years over 200 babies were born to women with mild
disorders of ovarian function who took safe, physiologic dosages of cortisone
or cortisol not only in order to get pregnant but also throughout their
pregnancies to protect against miscarriages, without any evidence or harm
to either mothers or babies (4). These dosages therefore appeared to be
restoring normal function rather than impairing it.
Some of these women reported that while taking the small, safe dosages
of cortisone or cortisol their symptoms of allergies, or unexplained chronic
fatigue (the chronic fatigue syndrome), or autoimmune disorders such as
rheumatoid arthritis or chronic thyroiditis, also improved. These beneficial
effects of safe, physiologic dosages of cortisone or cortisol were reported
at the annual meeting of the American College of Physicians in New York
City in April, 1966, and in a paper published in the Archives of Internal
Medicine in 1967 (5), but by that time patents on the normal hormones,
cortisone and cortisol, had expired. Pharmaceutical laws require that when
a new use is found for a medication, it must receive all of the relevant
tests for its safety, including therapeutic trials, before the new use
can be advertised. Because such studies are expensive, pharmaceutical companies
have little incentive for performing them when they no longer have the
protection for their investment that is provided by a patent. Hence pharmaceutical
companies apparently could not even mention in their package inserts or
advertisements any of these potential new uses of safe dosages of the normal
hormone, cortisol! Further reports of the beneficial effects of safe dosages
of cortisone or cortisol were published in endocrine journals and conference
proceedings in the 1960's and 1970's, but these were received skeptically
by most physicians when no ads or promotional efforts by the pharmaceutical
companies marketing the hormones appeared.
I, like most other physicians, did not realize the cause of this problem,
so I thought it might be helped by my writing a book reviewing the cortisone
story and describing the beneficial effects of safe, physiologic dosages
of cortisone or cortisol that had been observed. In 1981, therefore, Safe
Uses of Cortisone was published by the Charles C. Thomas Company, a
reputable medical publisher that had published much of the earlier work
on cortisone and its derivatives.
This book also received little attention until a few patients with chronic
allergies and their physicians found that this therapeutic approach was
both safe and effective. During the past five years, when it has become
evident that the hypothalamus-pituitary-adrenal (HPA) axis plays a major
role in immunity and in the response to stress, there has been a return
to considering the possibility that autoimmune disorders, especially rheumatoid
arthritis, and chronic allergic disorders might be related to mild adrenocortical
deficiency, either primary in the adrenal glands or secondary to deficient
stimulation by adrenocorticotropic hormone (ACTH) from the pituitary gland.
An update on Safe Uses of Cortisone entitled
Safe Uses of Cortisol
has therefore recently been published, reviewing these developments and
the evidence that mild adrenocortical deficiency, a diagnosis that is not
mentioned in medical textbooks, is very probably a factor in the development
of many, if not all, allergic disorders and autoimmune disorders, and describing
a safe treatment of these disorders with physiologic dosages of cortisol
(6). Hopefully this book will help to clarify this confusing situation.
Cortisol is a normal hormone, the only hormone that is absolutely essential
for life, so it must be safe in proper physiologic amounts!
These developments have therefore revealed a serious problem in our pharmaceutical
laws that will hopefully be corrected. If a cure for cancer were found
tomorrow in a medication whose patent had expired, especially one that
had developed a bad reputation like cortisone, it might be extremely difficult
to get anyone to pay any attention to it!
References
1. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effects of a hormone
of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: Compound E)
and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary
report. Proc Staff Meet Mayo Clin 1949, 24:181-97.
2. Jefferies, W.McK. The present status of ACTH, cortisone and related
steroids in clinical medicine. New Eng J Med 1955, 253:441-6.
3. Jefferies, W.McK. Glucocorticoids and Ovulation. In Greenblatt, R.B.(Ed):
Ovulation. Philadelphia, Lippincott,1966. pp 62-74.
4. Jefferies, W.McK. Safe Uses of Cortisol (second edition) Charles
C.Thomas, Springfield, 1996, p.86.
5. Jefferies, W.McK. Low dosage glucocorticoid therapy. Arch Intern Med
1967, 119:265-78.
6. Jefferies, W.McK. Safe Uses of Cortisol (second edition) Charles C.Thomas,
Springfield, 1996, Chapters 4 through 11.
Copyright © 1997-2002 William McK. Jefferies, M.D. All rights reserved.
Updated: 07/23/02